Vergelijking

Maridebart Cafraglutide vs. Pemvidutide

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Metabool

CAS-nr.

geen gegevens

Molecuulmassa

geen gegevens

Halfwaardetijd

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

Maridebart Cafraglutide

MariTide combines GLP-1 receptor agonism with GIP receptor antagonism in an antibody-peptide conjugate. Its long duration of action allows infrequent (monthly) dosing.

Pemvidutide

The GLP-1 component suppresses appetite while the glucagon component raises energy expenditure and acts directly on hepatic fat metabolism — the combination is intended to mimic the complementary effects of diet and exercise.

Bewijsbasis

Hoogste bewijs

Humane RCT

Humane studie

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Maridebart Cafraglutide	Pemvidutide
Duitsland	Niet goedgekeurd	Niet goedgekeurd
Verenigde Staten	Niet goedgekeurd	Niet goedgekeurd

Volledige vermeldingen

Maridebart Cafraglutide

Volledige vermelding →

Pemvidutide

Volledige vermelding →

Frequently asked questions

What is the difference between Maridebart Cafraglutide and Pemvidutide?: Maridebart Cafraglutide is classified as "Metabool", while Pemvidutide is classified as "Metabool". Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. Pemvidutide: Pemvidutide is a 29-amino-acid GLP-1/glucagon dual receptor agonist (Altimmune) under investigation for obesity and the fatty-liver disease MASH. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Maridebart Cafraglutide or Pemvidutide?: The highest available evidence level is "Humane RCT" for Maridebart Cafraglutide and "Humane studie" for Pemvidutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Maridebart Cafraglutide and Pemvidutide in Germany and the United States?: Duitsland: Maridebart Cafraglutide — Niet goedgekeurd, Pemvidutide — Niet goedgekeurd. Verenigde Staten: Maridebart Cafraglutide — Niet goedgekeurd, Pemvidutide — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.

Country

Maridebart Cafraglutide

Pemvidutide

Duitsland

Niet goedgekeurd

Verenigde Staten

Niet goedgekeurd

Frequently asked questions

What is the difference between Maridebart Cafraglutide and Pemvidutide?

Maridebart Cafraglutide is classified as "Metabool", while Pemvidutide is classified as "Metabool". Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. Pemvidutide: Pemvidutide is a 29-amino-acid GLP-1/glucagon dual receptor agonist (Altimmune) under investigation for obesity and the fatty-liver disease MASH. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Maridebart Cafraglutide or Pemvidutide?

The highest available evidence level is "Humane RCT" for Maridebart Cafraglutide and "Humane studie" for Pemvidutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Maridebart Cafraglutide and Pemvidutide in Germany and the United States?

Duitsland: Maridebart Cafraglutide — Niet goedgekeurd, Pemvidutide — Niet goedgekeurd. Verenigde Staten: Maridebart Cafraglutide — Niet goedgekeurd, Pemvidutide — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.